Picton Mahoney Asset Management Has $13.95 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Picton Mahoney Asset Management grew its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 50.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 633,149 shares of the company's stock after buying an additional 213,041 shares during the quarter. Picton Mahoney Asset Management owned approximately 0.06% of Teva Pharmaceutical Industries worth $13,953,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in TEVA. Smithfield Trust Co increased its holdings in shares of Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock valued at $50,000 after acquiring an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at approximately $50,000. Ameliora Wealth Management Ltd. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth $66,000. Venturi Wealth Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth $60,000. Finally, IFP Advisors Inc grew its stake in Teva Pharmaceutical Industries by 96.1% in the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after buying an additional 1,960 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Insider Activity

In other news, Director Roberto Mignone sold 286,000 shares of the company's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now owns 695,000 shares of the company's stock, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.55% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. StockNews.com lowered shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Friday, March 7th. Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Piper Sandler upped their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. Bank of America lowered their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Finally, UBS Group reduced their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA traded down $0.43 during trading hours on Tuesday, reaching $16.29. The stock had a trading volume of 3,016,452 shares, compared to its average volume of 9,358,820. Teva Pharmaceutical Industries Limited has a twelve month low of $12.51 and a twelve month high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The business's fifty day moving average is $18.19 and its two-hundred day moving average is $18.28. The company has a market cap of $18.46 billion, a price-to-earnings ratio of -11.23, a PEG ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.